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Abstract
Proteasome activity is an important part of viral replication. In this study, we examined the effect of proteasome inhibitors
on the replication of vesicular stomatitis virus (VSV) and poliovirus. We found that the proteasome inhibitors significantly
suppressed VSV protein synthesis, virus accumulation, and protected infected cells from toxic effect of VSV replication. In
contrast, poliovirus replication was delayed, but not diminished in the presence of the proteasome inhibitors MG132 and
Bortezomib. We also found that inhibition of proteasomes stimulated stress-related processes, such as accumulation of
chaperone hsp70, phosphorylation of eIF2a, and overall inhibition of translation. VSV replication was sensitive to this stress
with significant decline in replication process. Poliovirus growth was less sensitive with only delay in replication. Inhibition
of proteasome activity suppressed cellular and VSV protein synthesis, but did not reduce poliovirus protein synthesis.
Protein kinase GCN2 supported the ability of proteasome inhibitors to attenuate general translation and to suppress VSV
replication. We propose that different mechanisms of translational initiation by VSV and poliovirus determine their
sensitivity to stress induced by the inhibition of proteasomes. To our knowledge, this is the first study that connects the
effect of stress induced by proteasome inhibition with the efficiency of viral infection.
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Introduction
Proteasomes are cellular structures responsible for rapid,
efficient and strictly regulated process of protein degradation [1].
The substrates of degradation are first subjected to poly-
ubiquitination and then digested by the proteasomes [2]. The
ubiquitin/proteasome pathway is the major route for regulated
protein degradation in eukaryotic cells [1]. Besides special targets
for ubiquitination and proteasome-specific degradation, such as
p53, IkBa, STAT [3–6], proteasomes are responsible for the
degradation of unfolded or improperly folded proteins [7,8]. In
combination with chaperones, this activity of proteasomes is
important for maintaining cellular protein homeostasis [9,10].
Proteasome specific degradation is an important part of
replication of several viruses [11,12]. Some viruses developed
mechanisms to target cellular proteins, such as p53 and STAT, for
proteasome-specific degradation [13,14]. The stability of some
viral proteins, including poliovirus and HAV protein 3C, also
depends on the proteasome activity [15]. In the present work, we
studied the role of proteasomes in the replication of vesicular
stomatitis virus (VSV) and poliovirus.
VSV belongs to the Rhabdoviridae [16]. Rhabdoviruses have
negative strand RNA genomes, and their replication begins with
synthesis of positive strand mRNAs by viral RNA polymerase [17].
Similar to cellular mRNAs, VSV mRNAs are capped and
polyadenylated [18,19]. Replicating virus efficiently competes
with cellular processes for the substrates of RNA and protein
synthesis and for the translational machinery [20–23]. As a result,
virus proteins represent a sizeable share of newly synthesized
proteins in the infected cells.
Poliovirus belongs to the Enterovirus genus of the Picornavir-
idae [24]. Picornaviruses have positive-strand RNA genomes that
can be translated immediately after infection [25]. Unlike VSV
and most cellular mRNAs, the picornavirus translation initiation
occurs at an internal ribosome entry site (IRES) [26]. Poliovirus
replication triggers cleavage of eIF4G, which is needed for cap-
dependent initiation, leading to suppression of cellular protein
synthesis and rapid accumulation of viral proteins and RNA
[27,28].
Ubiquitination has broad effects on viral infections. For
example, the ability of ubiquitination to regulate endocytosis and
endosomal membrane transport [29] may contribute to the
maturation and budding of retroviruses [30,31] and paramyxovi-
ruses [32], including Rhabdoviruses, such as VSV and rabies virus
[32,33]. The role of free ubiquitin and proteasomes in the late
stage of VSV replication, including budding, was previously
postulated [33].
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VSV maturation and budding [33], we found a new effect of
proteasome inhibition on VSV protein synthesis and virus
accumulation. This effect is evident during early steps of VSV
replication. Proteasome inhibition had a detrimental effect on
VSV and cellular protein synthesis in virus-infected cells, and
protected the cells from the toxic effect of VSV infection. Negative
effect of proteasome inhibitors on VSV replication and cellular
protein synthesis was not detected in GCN22/2 cells. In contrast,
poliovirus replication was less sensitive to the effect of proteasomes
inhibitors. Inhibition of proteasome activity delayed all processes
during poliovirus replication, but did not abrogate them, and did
not change virus accumulation or its toxic effect. We suggest that
stress induced by accumulation of aberrant translation products
following proteasome inhibition leads to the suppression of cap-
dependent translation, explaining why proteasome inhibitors block
replication of VSV but not poliovirus replication.
Results
Inhibition of proteasome activity suppresses VSV
replication and protects the cells from infection
To study the effect of proteasome inhibitor on VSV replication,
HeLa cells were treated with various amounts of proteasome
inhibitor MG132 (Calbiochem) and simultaneously infected with
VSV overnight. Low concentrations of the inhibitor (1 to 10 mM)
did not have a visible toxic effect on cells after overnight
incubation. While infection with VSV at MOI=1 led to complete
destruction of untreated HeLa cells overnight, addition of MG132
in the indicated concentrations protected the cells from the toxic
effect of VSV infection. Reduced virus yield confirmed that
MG132 suppressed VSV replication in HeLa cells at concentra-
tions starting from 2.5 mM (Fig. 1A). To analyze VSV protein
synthesis, HeLa cells were infected with VSV at MOI=5 for 4 h
and treated with various amounts of MG132 at a time of infection.
Reduced levels of VSV protein were also observed by immuno-
blotting (Fig. 1B).
Additional experiments were performed by using immunopre-
cipitation of S
35 methionine/cysteine-labeled proteins from VSV
infected cells. HeLa cells were infected with VSV at MOI=5 for
4 h and treated with various amount of MG132 at a time of
infection. The newly synthesized proteins were labeled by S
35-
methionine and cysteine, and cytoplasmic protein extracts were
prepared according to Dingmans’ protocol [34]. Next, VSV
proteins P and N were precipitated from the cytoplasmic extracts
using respective antibodies. The efficiency of virus protein
synthesis was assessed by electrophoresis and autoradiography
(Fig. 1 C, D). A significant concentration-dependent suppression of
virus replication and viral protein synthesis by 5 and 10 mMo f
MG132 was observed in all experiments.
The time course analysis of MG132 inhibitory activity
In our original experiments, we treated VSV-infected cells with
MG132 at the start of infection. In the next experiment, HeLa
Figure 1. Proteasome inhibitor MG132 suppresses VSV replication and protein synthesis. (A) Titration of VSV in MG132 treated cells.
HeLa cells were infected with VSV (MOI=1) for one hour with additional washing and incubated overnight. Medium from control VSV infected cells
and VSV infected cells treated with 10 mM, 5 mM, 2.5 mM, and 1 mM of MG132 were used for plaque assay to detect virus replication. Results represent
average data of two experiments. (B) Western blotting with anti-P-protein antibodies. HeLa cells were infected with VSV (MOI=5) for 1 hour. After
changing the medium, MG132 was added in the indicated concentrations and the cells were incubated for additional 4 h. Total protein extracts
(5 mg) were analyzed with anti-P-protein Abs. Keratin 18 (K18) was a protein loading control. Intensity of each band was estimated with ImageJ
software to calculate percentage of viral protein synthesis inhibition. (C) Immunoprecipitation of S
35 labeled P-protein. HeLa cells were infected with
VSV (MOI=5) for 4 h. Proteins were labeled with S
35 methionine/cysteine for last 30 min of infection and VSV P-protein was precipitated with specific
antibodies from cytoplasmic protein extracts and analyzed by electrophoresis and autoradiography. MG132 was added for 4 h in indicated
concentrations. (D) Immunoprecipitation of S
35 labeled N-protein. The protein extracts described in panel C were precipitated with antibodies specific
to N-protein. Proteins were analyzed by electrophoresis and autoradiography.
doi:10.1371/journal.pone.0001887.g001
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two, and three hours after VSV infection to analyze the
connection between the effect of proteasome inhibitor and virus
internalization. The efficiency of virus replication after an
overnight infection with VSV at MOI=1 (Fig. 2A, C) or after
4 h at MOI=5 (Fig. 2 B, D) was evaluated by plaque assay (Fig,
2A), by Northern (Fig. 2B), by Western blotting of 5 mg of total
protein with anti-P-protein antibodies (Fig. 2 C), and by
immunoprecipitation of S
35-labeled P-protein (Fig. 2 D). Although
the inhibiting effect of MG132 on VSV replication was strongest
when the drug was added earlier, significant inhibition of VSV
replication was still detectable when MG132 was added 3 h after
VSV infection.
Detrimental effect of proteasome inhibition on VSV
replication does not depend on the inhibitor type
To confirm that inhibitory effect of MG132 is due to its
suppression of proteasome activity, we tested different proteasome
inhibitors. Proteasome inhibitor 1 is a modified tri-peptide with a
structure different from MG132. It proteasome-inhibiting activity
requires higher concentrations than MG132. In these experiments
MG132 served as a positive control. Both proteasome inhibitors
affected VSV replication in HeLa cells in a similar manner (Fig. 3
panels A and B). Bortezomib (PS341) is a specific inhibitor of
proteasomes, approved by FDA as anti-cancer drug [35]. Its
structure and mechanism of action is different from MG132 and
proteasome inhibitor 1. It is more active than MG132 and was
used at concentration as low as 100 nM. Bortezomib, like other
proteasome inhibitors, suppressed VSV replication (Fig. 3 panels A
and C).
Proteasome inhibitors delay the synthesis of poliovirus
proteins, RNA, and the accumulation of live virus
To understand the possible role of proteasomes in poliovirus
replication, we studied kinetics of virus infection by titration
infectious virus released into the medium of poliovirus-infected
HeLa cells with and without two-hour MG132 pre-treatment.
Although virus titers during late phases of viral infection (5–6 h)
were similar in control cells and in cells pre-treated with MG132,
virus accumulation was noticeably delayed between 3 and 4 h in
cells, in which proteasome activity was suppressed with MG132
(Fig. 4A). The efficiency of proteasome inhibitor was confirmed by
observing stabilization of IkBa in TNF-treated HeLa cells (Fig. 4B)
[36]. As an independent confirmation of the changes in the kinetic
of poliovirus accumulation in cells pre-treated with proteasome
inhibitor, we found that the appearance and accumulation of
poliovirus capsid proteins was similarly delayed in cells pre-treated
with MG132 (Fig. 4C). In the same way, the appearance of viral
non-structural proteins 3C and 3A/3AB was also delayed by one
hour in MG132 treated poliovirus-infected cells (Fig. 4D).
Bortezomib had similar effect on poliovirus replication (Fig. 4E).
In agreement with the immunoblotting data, as assessed by
Northern blot there was a delay in the accumulation of viral
genomic RNA in MG132 pretreated cells (Fig. 5A).
Inhibition of proteasome activity does not affect
poliovirus cell entry
The delay of poliovirus replication in MG132 treated cells could
be the result of less efficient entry of poliovirus into HeLa cells
treated with MG132. To study the efficiency of the entry of
Figure 2. The effect of MG132 on VSV replication at different time of infection. (A) Titration of VSV virus from medium of overnight
infected HeLa cells. HeLa cells were infected with VSV MOI=1. The incubation of the cells with virus lasted one hour with additional washing. 5 mMo f
MG132 were added to cells at time of infection (15 h), 1 h (14 h), 2 h (13 h), and 3 h (12 h) after VSV infection. Results represent average data of two
experiments. (B) VSV mRNA synthesis in MG132 treated cells. Northern blot analysis of 10 mg of total RNA from VSV (MOI=5) infected for 4 h cells
treated with MG132 at a time of infection (4 h), or 1 h after infection (3 h). Hybridization with P
32 labeled P-protein cDNA probe. RNA loading was
standardized by hybridization with GAPDH-gene probe. The hybridization signal of each band was estimated by ImageJ software to calculate
percentage of RNA synthesis inhibition. (C) Immunoblotting with anti P-protein Abs. HeLa cells were infected with VSV (MOI=1) and treated with
5 mM of MG132 as indicated in panel A. Total protein extracts (5 mg) from these cells were purified and tested by Western blotting with anti-P-protein
Abs. Keratin 18 was a protein loading control. (D) Immunoprecipitation of S
35-methionine labeled P-protein from VSV infected cells. HeLa cells were
infected with VSV (MOI=5) and treated with 5 mM of MG132 at time of infection (4 h), 1 h after infection (3 h), or 2 h after infection (2 h). After 4 h of
infection the cells were incubated with S
35-methionine/cysteine for 30 min. Cytoplasmic protein extracts were purified and VSV P-protein was
precipitated with anti-P-protein Abs. The efficiency of P-protein synthesis was estimated by electrophoresis and autoradiography.
doi:10.1371/journal.pone.0001887.g002
Proteasome Inhibition
PLoS ONE | www.plosone.org 3 April 2008 | Volume 3 | Issue 4 | e1887poliovirus into HeLa cells, we tested for the presence of S
35-labeled
poliovirus capsid proteins in HeLa cells after incubation of HeLa
cells with S
35-labeled poliovirus. In this experiment, HeLa cells
were incubated with poliovirus for one hour at 4uC, the virus-
containing medium was removed, and cells were incubated for
additional hour at 37uC. Proteins from cells were analyzed for S
35-
labeled virus capsid proteins by electrophoresis and autoradiog-
raphy. A similar amount of capsid proteins from infecting virus
could be detected during the first hour of infection regardless of
whether cells were treated with proteasome inhibitor (Fig. 5B).
Later during infection, capsid proteins accumulated sooner in
control cells than in MG132-treated cells (Fig. 5C)
Poliovirus-specific proteolytic cleavage of p65-RelA and
eIF4G proteins is delayed by a proteasome inhibitor
Recently, we described the ability of poliovirus to cleave the p65-
RelA subunit of NFkB transcription factor near its C-terminus
[37]. This cleavage is protease 3C-specific and takes place between
2 and 3 h of infection in HeLa cells. The suppression of
proteasome activity delayed the p65-RelA protease 3C-specific
cleavage by about 60 min (Fig. 6A). These data indicate that the
proteasome inhibitor MG132 did not stop the process of protease
3C-specific cleavage of p65-RelA in poliovirus-infected cells. Also,
addition of MG132 to uninfected cells did not result in measurable
increase of p65-RelA level. This suggests that slowing of p65-RelA
degradation in poliovirus-infected cells treated with the proteasome
inhibitor could be explained by the delay in synthesis of viral
protease 3C that mediates this degradation.
The ability of the poliovirus protease to cleave the eIF4G
translational initiation factor is an important step in the viral
replicative cycle [38,39]. This mechanism allows poliovirus to
compete with cellular mRNAs for translation machinery and to
inhibit many cellular defense responses that require synthesis of
new antiviral proteins. The process of eIF4G degradation is one of
the earliest events in poliovirus infection, occurring during first
90 min of infection in HeLa cells and depending on poliovirus
protease 2A activity. Treatment of poliovirus-infected HeLa cells
with a proteasome inhibitor delayed cleavage of p220 eIF4G
protein (Fig. 6B). Thus, inhibition of proteasomes delayed, but did
not abrogate virus specific cleavage of cellular proteins.
Proteasome inhibition delays synthesis of poliovirus
proteins
Accumulation of virus capsid protein and non-capsid proteins
3C, 3A, and 3AB was delayed in MG132 treated cells (Fig. 4 C,
D). To study the process of poliovirus protein synthesis in more
detail, HeLa cells were infected with poliovirus for 2, 3, and 4 h,
and S
35 methionine/cysteine was added for 30 min at the end of
each period. Capsid proteins were detected by immunoprecipita-
tion, electrophoresis and then autoradiography (Fig. 7A, B). Again,
the accumulation of de novo synthesized capsid proteins was
delayed but not eliminated in MG132 treated cells.
No additional accumulation of capsid protein precursor P1 was
detected in MG132 treated cells, indicating that MG132 did not
suppress the activities of poliovirus proteases.
The effect of inhibition of proteasome activity on cellular
translation
VSV and poliovirus infections suppress translation of cellular
RNAs [40–43]. To analyze the translational activity in the cells
treated with MG132 and infected with VSV or poliovirus, we
labeled cellular proteins in vivo with S
35 methionine/cysteine and
Figure3.DifferentproteasomeinhibitorsaffectVSVreplication.(A)Proteasomeinhibitor1andBortezomibdecreasedVSVreplication.Titration
of VSV from the medium of overnight infected HeLa cells. VSV infection (MOI=1) for one hour was substituted by the regular medium with indicated
concentration of proteasome inhibitors. VSV was titrated by plaque assay after overnight growth. (B) Analysis of P-protein synthesis in the cells treated
with proteasome inhibitor 1. HeLa cells were infected with VSV (MOI=5) for 4 h and treated with proteasome inhibitor 1 (PI) or MG132 (MG) at a time of
VSV infection. The total protein extracts (5 mg) from these cells were analyzed by Western blotting with anti-P-protein Abs. The concentrations of
proteasomeinhibitors variedfrom5 to20 mM.Keratin 18(K18)wasaprotein loadingcontrol.(C) Bortezomib suppressedVSVreplication.HeLacellswere
infected with VSV, treated with Bortezomib (100 nM) and MG132 (5 mM), and analyzed as described in panel B. K18 was a protein loading control.
doi:10.1371/journal.pone.0001887.g003
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Infection of HeLa cells with VSV and poliovirus decreased general
cellular protein synthesis (Fig. 8A, 7A). Treatment of HeLa cells
with MG132 suppressed cellular protein synthesis (Fig. 8A, 7A).
This effect was also confirmed by the analysis of actin synthesis in
MG132 treated cells (Fig. 8 B, C). In contrast to cellular protein
synthesis, the accumulation of poliovirus capsid proteins was only
slightly delayed in HeLa cells pre-treated with MG132 (Fig. 7B).
Proteasome inhibition stimulates accumulation of
chaperone hsp70 and the phosphorylation of eIF2a
Inhibition of general translation is a common consequence of
various stress stimuli [44,45]. Phosphorylation of eIF2a and
accumulation of chaperone molecules are additional markers of
the stress response [46]. We analyzed the appearance of these
markers in HeLa cells treated with MG132. S
35 pulse-labeled
cytoplasmic protein extracts were purified and precipitated with
anti-hsp70 antibodies for examination by electrophoresis and
autoradiography. The results of these experiments are presented in
Fig. 9 A. A newly synthesized 70 kD protein corresponding to
hsp70 accumulated in all cells treated with MG132. Phosphory-
lation of eIF2a in MG132 treated cells was detected with
antibodies specific to the phosphorylated form of eIF2a.
Phosphorylation of eIF2a was detected in MG132-treated cells
and in cells treated with another stress-inducing agent thapsigargin
(an inhibitor of a sarco-endoplasmic reticulum Ca
+2 ATPase), but
Figure 4. Proteasome inhibitors delay the replication of poliovirus. (A) HeLa cells (triangles) and HeLa cells pre-treated for 2 h with 5 mM
proteasome inhibitor MG132 (squares) were infected with poliovirus strain Mahoney (MOI=5) for 1 h. After replacement of medium, the
accumulation of virus in medium was estimated by titration. (B) MG132 inhibits TNF-specific degradation of IkBa. Control HeLa cells and HeLa cells
pretreated with 5 mM MG132 for 2 h were incubated with 1 ng/ml of human TNF for 20 min. 10 mg of total protein extracts were analyzed with anti-
IkBa Abs. (C) HeLa cells and HeLa cells pre-treated with MG132 were infected with poliovirus (MOI=5) for 1 h. After medium replacement, protein
extracts were collected at different times of infection. The accumulation of poliovirus capsid proteins was tested in Western blotting experiments
from 10 mg of protein extracts. (D) The protein extracts described in section B were tested with anti-proteins 3C and 3A Abs. The accumulation of
poliovirus proteins 3C, 3A and 3AB were detected in 10 mg of protein extracts. (E) Bortezomib treatment attenuated poliovirus replication. HeLa cells
were pretreated with Bortezomib for 2 h, then infected and analyzed as described in panels C and D. K18 was a loading control. Hsp70 is a control of
Bortezomib activity.
doi:10.1371/journal.pone.0001887.g004
Proteasome Inhibition
PLoS ONE | www.plosone.org 5 April 2008 | Volume 3 | Issue 4 | e1887was not detected in control HeLa cells (Fig. 9B). Thus, inhibition
of proteasomes stimulated the appearance of stress markers, such
as inhibition of general translation, phosphorylation of eIF2a, and
the accumulation of chaperone hsp70.
GCN2 activity is important for detrimental effect of
proteasome inhibitor on VSV replication
GCN2 is a protein kinase responsible for eIF2a phosphorylation
in response to amino acid starvation and some other stresses
[44,47]. Proteasome inhibitors’ induced stress and attenuated
translation is GCN2-dependent [44,47]. To prove the role of stress
induced by proteasome inhibition in suppression of VSV
replication, we used wild type (wt) GCN2+/+ MEF and
GCN22/2 MEF for VSV infection. Inhibition of proteasome
activity attenuated general translation in wt GCN2+/+ MEF, but
did not have effect on protein synthesis in GCN22/2 cells
(Fig. 10A). MG132-specific phosphorylation of eIF2a factor was
less efficient in GCN22/2 than in wt GCN2+/+ MEF cells
(Fig. 10B). In agreement with these data, VSV replication was
affected by inhibitors of proteasomes in wt GCN2+/+ MEF, but
was not changed in GCN22/2 cells (Fig. 10 C, D). Surprisingly,
GCN2 activity suppressed VSV replication in MEF without
additional treatment with proteasome inhibitors (Fig. 10 C, D).
Phosphorylation of eIF2a during VSV and poliovirus
infection
Virus infection is often connected with stress-related cellular
processes, including induction of PKR- specific phosphorylation of
eIF2a by double stranded viral RNAs [44,48]. We analyzed the
ability of poliovirus and VSV to activate eIF2a phosphorylation at
4 h after infection (Fig. 11). Poliovirus infection stimulated
phosphorylation of translation initiation factor at 4 h after
infection. In contrast, VSV infection did not induce phosphory-
lation of eIF2a at this time of infection. Our data coincide with
earlier reports [49,50]. According to these publications, eIF2a
phosphorylation may be detected in poliovirus infected cells
starting from 3 h post-infection, but in VSV infected cells eIF2a
phosphorylation was detected only after 8 h of infection [49,50].
Thus, there is a correlation between the ability of viral infection to
stimulate eIF2a phosphorylation and its resistance to this
phosphorylation stimulated by other stimuli, such as proteasome
inhibitors.
Discussion
Ubiquitination is important in the budding of retroviruses and
Paramyxoviruses such as Sendai virus, VSV, and rabies virus
[30,32,33]. Replication of coxsackieviruses was sensitive to
inhibitor of proteasomes [51]. During late steps of Paramyxovirus
replication, there is a decrease in accumulation of infectious virus
in culture medium, but no change in the efficiency of virus protein
synthesis with high concentrations of MG132 (up to 100 mM)
Figure 5. (A) The accumulation of poliovirus RNA was delayed
but not abolished in MG132 treated poliovirus-infected cells.
Northern blot hybridization of 5 mg of total RNA from poliovirus
infected cells with poliovirus protein 3C hybridization probe. Hybrid-
ization with GAPDH gene was a RNA loading control. (B) The inhibition
of proteasome activity does not affect the entrance of poliovirus into
the cells. MG treated and control HeLa cells were pre-incubated with
S
35-labeled poliovirus (MOI=100) for 1 h at 4uC. To estimate adsorption
background, cells (ad) were washed with cold PBS. Virus internalization
(in) was estimated by accumulation of S
35-labeled poliovirus capsid
proteins during additional 1 h incubation at 37uC. S
35-labeled proteins
were analyzed by electrophoresis and autoradiography. (C) Poliovirus
capsid proteins accumulate slower in MG132 pretreated cells. The
extracts from poliovirus-infected cells were analyzed with anti-
poliovirus capsid Abs. Control or MG132 2 h pretreated cells were
incubated with poliovirus (MOI=5) for 1 h. Virus containing medium
was washed out and cells were incubated for indicated time. 10 mgo f
protein from infected cells were analyzed by Western blotting with anti-
poliovirus capsid Abs.
doi:10.1371/journal.pone.0001887.g005
Figure 6. Proteolytic cleavage of p65-RelA and eIF4G occurred
later during poliovirus infection of the cells with inhibited
proteasome activity. HeLa cells and MG 132 2 h pretreated HeLa
cells were infected with poliovirus (MOI=5) for 1 h. After change of
medium, total protein extracts were collected every hour and tested
with anti-p65-RelA C-terminus specific Abs (A) or with anti eIF4G N-
terminus specific Abs (B). 10 mg of protein were tested in Western
blotting experiments.
doi:10.1371/journal.pone.0001887.g006
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2 h were infected with poliovirus (MOI=5) for 2, 3 and 4 h. All cells were incubated in methionine/cysteine free medium supplemented with S
35-
methionine/cysteine for last 30 min before harvesting. To study general translation, 10 mg of cytoplasmic protein extracts were separated by
electrophoresis and analyzed by autoradiography (A). To study poliovirus capsid protein accumulation, capsid proteins were precipitated by specific
Abs from 100 mg of cytoplasmic protein extracts and analyzed by electrophoresis and autoradiography (B).
doi:10.1371/journal.pone.0001887.g007
Figure 8. The effect of MG132 and virus infection on cellular protein synthesis. (A) Protein extracts were purified from control HeLa cells,
cells infected with VSV for 4 h, cells treated with 5 mM of MG132 for 4 h, and cells infected with VSV and treated with MG132 for 4 h. All cells were
incubated with S
35 methionine/cysteine for last 30 min before the protein extracts purification. Cytoplasmic protein extracts were analyzed by
electrophoresis and autoradiography. (B) Cytoplasmic protein extracts from control, VSV infected, and MG treated cells were precipitated with anti-
actin Abs, and the complexes were purified on protein A agarose. S
35 labeled actin was analyzed by electrophoresis and autoradiography. (C)
Cytoplasmic S
35-labeled protein extracts from MG-treated and poliovirus-infected cells were precipitated with anti-actin Abs and analyzed as
described in panel B. All protein bands’ intensity was detected by ImageJ software to calculate percentage of protein synthesis inhibition.
doi:10.1371/journal.pone.0001887.g008
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inhibitors on the replication of VSV and poliovirus, and
demonstrate that these viruses differently respond to the inhibition.
We present data indicating that the proteasome inhibition by
5 mM of MG132 ,10 mM of proteasome inhibitor 1, and 100 nM
of Bortezomib at the early steps of VSV infection suppressed virus
accumulation more than 100 fold and affected the synthesis of
VSV proteins P and N. Proteasome inhibition decreased the
efficiency of VSV replication when was administrated at the time
of infection, as well as after it, indicating that the effect of MG132
on VSV replication does not depend on VSV entry into the cells.
Treatment of VSV infected cells with MG132 slightly decreased
the efficiency of VSV mRNA synthesis, which may be a
consequence of the less efficient synthesis of VSV RNA
polymerase L. This decline in the amount of RNA leads to
further decrease in the amount of viral proteins.
In contrast to VSV, inhibition of proteasomes in HeLa cells
delayed all processes during poliovirus replication by 60 to 90 min,
but did notabolish the accumulation of poliovirus.Ourdata contrast
with the effect of proteasome inhibitors on coxsackievirus replication
in cardiomyocytes published by Luo H. [51]. The authors analyzed
virus accumulation and synthesis of proteins and RNA at 7 h after
infection, but did not analyze the kinetics of coxsackievirus
replication. One explanation is that inhibitors of proteasomes may
also delay coxsackievirus replication in cardiomyocytes, because 7 h
of coxsackievirus replication may correspond to 3 h of poliovirus
replication in HeLa cells. A longer observation period would be
needed to see the effect. The alternative explanation may be the use
of different cell lines for virus growth. Cardiomyocytes may respond
differently to proteasome inhibition than do HeLa cells, resulting
different effect on the efficiency of viral replication.
Proteasome-specific degradation of cellular proteins is an
important mechanism for regulation of numerous cellular
processes, including activation and inhibition of specifically
regulated transcription and signal transduction, apoptosis, and
the cell cycle [52]. In these processes, proteasomes are the essential
components of the pathway that provides specific degradation of
ubiquitinated substrates. Some viruses are able to target cellular
proteins to proteasome-specific degradation [1,53].
Another function of proteasomes is to maintain cellular protein
homeostasis by degrading improperly folded, partially folded, or
unfolded proteins [54]. Significant part of newly synthesized cellular
proteins cannot fold correctly during synthesis. These unfolded
proteins are called defective ribosome products [55]. Cells have two
systems that deal with protein misfolding problem: the molecular
chaperones and the ubiquitin-proteasome system [54]. The
abundance of unfolded proteins increases under conditions when
cells synthesize more proteins, for example during viral infection.
The excess of newly synthesized unfolded proteins can lead to their
aggregation with each other or other proteins. Translational
attenuation is one of the responses to this stress [56,57], and is
mediated by phosphorylation of initiation factor eIF2a [47,56],
which is a common mechanism for regulation of protein synthesis
[46,48,58]. Inhibition of translation in cells treated with MG132
was also dependent on the phosphorylation of eIF2a [47]. VSV
replication, aswell as synthesis of VSV proteins, and most of cellular
proteins are sensitive to eIF2a phosphorylation [49], which blocks
recycling of this essential component of cap-dependent initiation of
translation. VSV infection does not induce eIF2a phosphorylation,
at least until the late stage of infection [49].
A plausible explanation of suppression mechanism of VSV
replication by proteasome inhibitors involves generation of stress
in cells with decreased proteasome activity [47]. In our
experiments, HeLa cells treated with MG132 and Bortezomib
responded with accumulation of a chaperone protein hsp70,
phosphorylation of eIF2a, and suppression of general translation.
In agreement with the role of GCN2 in MG132 induced stress
[47], the effect of proteasome inhibitors on VSV replication
depended on GCN2 activity in the process of stress-related
inhibition of translation. GCN2 activity protected fibroblasts from
VSV infection [59], and detrimental effect of proteasome
inhibitors on VSV replication was stronger in wt GCN2+/+
MEF cells than in GCN22/2 MEF, where MG132-specific
attenuation of translation and eIF2a phosphorylation were not
efficient. This is the direct indication that stress is the main reason
of VSV replication inhibition. The stress may be more profound in
MG 132 treated cells infected with VSV. These cells have an
abundance of newly synthesized proteins that must be folded with
Figure 9. Treatment with MG132 activates stress. (A) Inhibition of
proteasome activated hsp70 synthesis. Control HeLa cells, cells treated
for 4 h with MG132, and 4 h VSV-infected cells were incubated for last
30 min with S
35 methionine/cysteine. Cytoplasmic proteins were
precipitated with anti-hsp70 and anti-P-VSV Abs. Precipitated proteins
were analyzed by electrophoresis and autoradiography. (B) MG132
stimulated eIF2a phosphorylation. HeLa cells were treated with 1 mMo f
thapsigargin for 1 h and with 5 mM of MG132 for 4 h. 10 mg of protein
extracts were analyzed with Abs specific for eIF2a and eIF2a- phosphate
(eIF2a-P). Hsp70 is a marker of MG132 activated stress. Keratin 18 (K18)
is a loading control.
doi:10.1371/journal.pone.0001887.g009
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amount of improperly disposed unfolded cellular and viral
proteins. Viral infection may also prevent the additional synthesis
of cellular chaperones amplifying stress-related inhibition of
translation. This eFI2a-phosphorylation dependent inhibition of
translation affects translation of cellular mRNAs as well as VSV
mRNAs. Inefficient translation of VSV mRNA decreases the
amount of newly synthesized RNA polymerase L, which further
affects the synthesis of viral mRNA and proteins. As a result, viral
replication decreased up to 100-fold, which protects the cells from
some of the toxic effects of VSV infection. Although we did not
study the kinetics of VSV replication in MG132 treated cells, even
after overnight infection, markers of viral infection were
significantly suppressed in cells with decreased proteasome
activity. Thus proteasome inhibition may represent a novel
therapeutic approach against some viral infections, such as VSV.
In contrast with cellular and VSV protein synthesis, poliovirus
protein synthesis was only delayed by proteasome inhibition.
Similar delays in replication were reported for Sindbis virus by
brefeldin A generated stress [60], and for poliovirus in the cells
treated with an inhibitor of the RNA helicase eIF4A [61].
Although the mechanism of the delay is under investigation, the
low sensitivity of poliovirus infection to the stress produced by
proteasome inhibitor can be due to its IRES-dependent transla-
tion. Stress related phosphorylation of eIF2a decreases the general
level of translation, but the efficiency of translation of several
cellular mRNAs increases during the stress [62–64]. Cellular
chaperones hsp70 and GRP78, and SNAT2 neutral amino acid
transporter are among the genes whose expression increases
Figure 10. Inhibition of VSV replication in MG132 treated fibroblasts depends on GCN2. (A) Attenuation of translation in MG132- (MG),
and Bortezomib (Bort) -treated cells is GCN2-dependent. Control wt GCN2+/+ MEF and GCN22/2 MEF, or cells treated with proteasome inhibitors for
4 h were incubated with S
35-methionine/cysteine for 30 min. Protein synthesis was estimated by electrophoresis and autoradiography. (B) Western
immunoblotting analysis of GCN2-dependent phosphorylation of eIF2a in response to MG132. 10 mg of protein extracts from control and MG132
treated cells were analyzed with indicated antibodies. Efficiency’s fold of eIF2a phosphorylation (Phosp(x)) was estimated with ImageJ software. (C, D)
Replication of VSV was not affected by proteasome inhibitors in GCN22/2 MEF. Proteasome inhibitors were added 1 h after infection with VSV
(MOI=1) and cells were incubated over night. Replication of VSV was estimated by titration in two experiments (C), or by Western immunoblotting
with anti P-VSV protein Abs (D). Tubulin (tub) is a protein loading control.
doi:10.1371/journal.pone.0001887.g010
Figure 11. Different activation of eIF2a phosphorylation by
VSV and poliovirus infections. HeLa cells were infected with VSV for
4 h, infected with poliovirus for 4 h, or treated with 1 mMo f
thapsigargin for 1 hour. Cytoplasmic protein extracts from these and
control cells were analyzed with Abs against eIF2a and phosphorylated
form of eIF2a (panel A). Same membrane was analyzed with Abs against
VSV P- protein and poliovirus capsid proteins (panel B).
doi:10.1371/journal.pone.0001887.g011
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translation is a mechanism to support translation during stress
[68,69]. IRES-dependent translation is less reliant on standard
translation initiation factors. Translation from IRES of dicistro-
viruses does not require any translational initiation factors [70,71].
Translation from HCV IRES is resistant to decrease in the
amount of eIF2a [72,73]. Poliovirus infection stimulated the
phosphorylation of eIF2a [50]. We suggest that IRES-dependent
poliovirus translation confers resistance to the inhibition of
translation stimulated by stress due to proteasome inhibitor’s
treatment. Although learning the details of this effect will require
additional studies, it may represent a general mechanism of viral
stress resistance.
In conclusion, the proteasome inhibition initiated stress-related
processes in the cells. These processes included the GCN2-specific
phosphorylation of eIF2a, inhibition of general translation, and
accumulation of chaperone protein hsp70. Although stress is a
general inhibitor of viral replication, its efficacy differs for some
viruses. Cap-dependent translation of VSV mRNA is sensitive to
the stress, and as a result, the proteasome inhibition had a
detrimental effect on VSV replication. In contrast, cap-indepen-
dent IRES-dependent translation of poliovirus RNA was less
sensitive to the stress produced by proteasome inhibitors and by
poliovirus replication. As a result, the replication of poliovirus was
delayed but not abolished in HeLa cells treated with MG132 and
Bortezomib. To further substantiate this explanation, we are
studying the effects of similar stresses on other Picornaviruses and
Rhabdoviruses.
Materials and Methods
Cell culture, DNA transfection, virus infection, and
titration
HeLa, wt GCN2+/+ MEF, and GCN22/2 MEF were
cultured in Dulbecco modified Eagle’s medium (Invitrogen/Gibco
BRL) supplemented with 10% fetal calf serum. HeLa cells were
infected with poliovirus type 1 Mahoney strain at an input
multiplicity of infection (MOI) of 5 plaque-forming units (PFU)/
cell for 1h–6 h [74]. HeLa and MEF cells were infected with VSV
strain New Jersey with 5 PFU/cell for 1–5 h, or with 1 PFU/cell
overnight. For poliovirus titration, 10-fold serial dilutions (1:10 to
1:10
9) of the culture medium were added in duplicate to HeLa
cells cultured in 48-well plates. Poliovirus titer was determined by
the cytopathic effects visible after 3 days. VSV titer was
determined in duplicate by plaque assay of 10 fold serial dilutions
(1:10
4 to 1:10
7) of culture medium. MG132 and proteasome
inhibitor 1 were obtained from Calbiochem. Bortezomib was
provided by Roswell Park Hospital.
Western immunoblotting
Total protein extracts from HeLa and BHK cells were prepared
in RIPA buffer (150 mM NaCl, 1% SDS, 10 mM Tris (pH 8.0),
1% sodium deoxycholate, 1% NP-40) containing a protease
inhibitor cocktail (Sigma). Protein extracts were separated by
electrophoresis in 4–20% gradient polyacrylamide gels with SDS
(Invitrogen/Novex) and then transferred to nylon PVDF mem-
branes (Amersham). The following antibodies were used: anti-
VSV P- and N-protein antibodies obtained by immunization of
rabbits, anti-protein 3A mouse monoclonal antibodies were the
gift from Dr. K. Kirkegaard, anti-protein 3C rabbit antibodies
were a gift from Dr. B. L. Semler, anti-poliovirus capsid proteins
antibodies obtained by immunization of rabbits with purified
poliovirus, anti-p220 eIF4G mouse antibodies were a gift from Dr.
T. Pestova, anti-p65-RelA C-terminus rabbit antibodies (Santa
Cruz Biotechnology), anti-IkBa rabbit antibodies (Santa Cruz
Biotechnology), anti actin rabbit antibodies (Santa Cruz Biotech-
nology), anti-GCN2 rabbit antibodies (Santa Cruz Biotechnology),
and anti-hsp70 rabbit antibodies (Assay Designs/StressGen).
Phosphorylation of eIF2a was studied with anti-eIF2a and
eIF2a-phospate specific antibodies (Cell Signaling Technology).
Immune complexes were visualized by enhanced chemilumines-
cence (PerkinElmer Life Sciences). The control of protein loading
in the gel was done with rabbit anti-Hsp90 antibodies (Abcam,
Inc), anti-tubulin rabbit antibodies (Santa Cruz Biotechnology),
and anti-keratin 18 rabbit antibodies (a gift from Dr. R. Oshima).
HRP-conjugated secondary anti-rabbit and anti-mouse antibodies
were purchased from Santa Cruz Biotechnology. Band intensities
were quantified using NIH ImageJ software to calculate
percentage of protein accumulation (acc), cleavage (cl), phosphor-
ylation (Phosp), or inhibition of protein synthesis (inh).
Northern blotting
Total RNA from poliovirus or VSV infected HeLa cells were
analyzed by Northern blot hybridization with probes specific to
poliovirus RNA (3C-coding PCR fragment), VSV P-protein
cDNA, and GAPDH gene. A PCR fragment was generated from
poliovirus genomic cDNA with the primers specific for poliovirus
3C coding sequence (3Cs 59 GGG CCT GGG TTT GAC TAT
39; 3Ca 59 TTG GCT CTG AGT GAA GTA TGA 39). The VSV
P-protein cDNA probe was generated by PCR from a plasmid
containing genomic VSV cDNA with the primers corresponding
to 59 and 39 ends of P-protein cDNA (P-VSVs 59 GAC ACA GAA
TCT GAA CCA GAA ATT GAA 39, P-VSVa 59 TTA TGA
GAC ATT CGT CCG TTA CCT CCG 39). Quantitation of the
hybridization signals was done by NIH ImageJ software.
In vivo S
35-protein labeling and immunoprecipitation
HeLa cells were infected with VSV or poliovirus for the
indicated times and treated with MG132. Regular medium was
changed to a methionine/cysteine free medium supplemented
with S
35 methionine and S
35 cysteine (50 mCi/ml) (New
England Nuclear), and the cells were incubated for 30 min.
Cytoplasmic protein extracts from HeLa cells were purified
according to the Dignam protocol [34]. Viral and cellular
proteins were precipitated from cytoplasmic extracts with
corresponding antibodies overnight at 4uC. Antigen/antibody
complexes were purified on protein A Sepharose (Sigma) during
1 h incubation. Eluted proteins were analyzed by electrophoresis
and autoradiography.
Poliovirus adsorption and internalization
Poliovirus was labeled by S
35-methionine/cystein during
replication. HeLa cells were incubated with labeled poliovirus
(MOI=100) at 4uC for one hour. Control cells were washed 3
times with cold PBS and protein extracts were collected with
RIPA. To estimate virus internalization, after incubation with
labeled virus at 4uC, medium was changed and cells were
transferred to 37uC for additional one hour. Cells were washed 3
times with PBS and protein extracts were collected with RIPA.
Presence of S
35-labeled poliovirus capsid proteins were analyzed
by electrophoresis and autoradiography. Band intensities were
quantified using NIH ImageJ software to calculate percentage of
protein adsorption (ad) and internalization (in).
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